September 11, 2018

autoRIC® Trial Enrollment Complete in North America

CellAegis Announces Completion of Patient Enrollment in First North American Study for Innovative Heart Attack Therapy Using autoRIC®

June 14, 2018

Enrollment Completed in ERIC-PPCI Hospital Trial

CellAegis Announces Completion of Patient Enrollment in UK Investigator Sponsored Clinical Trial using autoRIC® Device

May 14, 2018

Patient Enrollment Completed in autoRIC® Trial

CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device

April 24, 2018

CellAegis Announces First Distribution Agreement for autoRIC® in Europe

TORONTO, Canada, April 24, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced that it has entered into a definitive agreement with Cardiologic Ltd., for the marketing and distribution of its autoRIC® device in the United Kingdom (“UK”) and Ireland.

April 17, 2018

CellAegis Strengthens Management Team to Support Future Growth

TORONTO, Canada, April 17, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced the strengthening of its management team with the recent appointments of Brian Fielding as Chief Financial Officer, and Hans Custers as VP, Sales and Marketing Europe.

April 10, 2018

CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial

TORONTO, Canada, April 10, 2018 (GLOBE NEWSWIRE) – CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced enrollment of the first patients in a U.S. clinical trial (“SHIELD”) of its autoRIC® device.

March 14, 2017

CellAegis Devices Announces US $9.5 Million Financing to Support Clinical and Regulatory Advancement of its autoRIC® Device

March 14, 2017 Toronto, Canada – CellAegis Devices Inc, a Toronto-based medical device company, today announced closing a US $9.5 million Series C financing to support a U.S. clinical trial and de novo 510(k) regulatory filing for marketing of its autoRIC Device as an adjunct therapy to stenting.

July 25, 2016

Peel-Halton Region Aims to minimize Damage to Heart Attack Patients

Automated non-invasive RIC therapy is the result of Canadian innovation and development.

July 6, 2015

RSK Medical and CellAegis Devices partner in the Canadian Healthcare Market

RSK Medical and CellAegis Devices partner in the Canadian Health Care Market to improve outcomes for heart attack patients.

Get autoRIC®